IP Library Granted Patent US 10,058,563
Granted Patent B2
US 10,058,563 · App. 15/478,368 · Granted Aug 28, 2018

System and method for diagnosis and treatment

Inventors: Randice Lisa Altschul (Cliffside Park, NJ); Neil David Theise (New York, NY); Myron Rapkin (Indianapolis, IN); Rebecca O'Brien (Shell Knob, MO)
A61K31/58
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,058,563
App. No.
15/478,368
Granted
Aug 28, 2018
Kind
B2
Abstract

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and/or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

Claims (6)

1. A method for low toxicity chemo treatment by targeted liver infusion in patients with forms of established cirrhosis that are high risk for emergence of HCC, including those with premalignant lesions diagnosed on biopsy or by radiology, comprising targeted delivery of ORG 34517 to intrahepatic lesions, wherein the targeted delivery of ORG 34517 to intrahepatic lesions treat emergence of hepatocellular carcinoma (HCC).

2. The method of claim 1 , wherein the patient with HCC is not a candidate to undergo surgical intervention.

3. The method of claim 1 , wherein the HCC resides in locations where surgical or ablative interventions are not available.

4. The method of claim 1 , wherein the patient with HCC has cirrhosis that is too advanced to make partial hepatectomy safe.

5. The method of claim 1 , wherein the patient with HCC is too early in their chronic liver disease to qualify for transplantation.

6. The method of claim 1 , wherein the HCC is too advanced for localized treatments.

Continuity (10)
Division 15095248 · Apr 11, 2016
Division 14802060 · Jul 17, 2015
Continuation In Part 14100714 · Dec 9, 2013
Division 13364651 · Feb 2, 2012
Provisional Application 61519323 · May 20, 2011
Provisional Application 61518248 · May 3, 2011
Provisional Application 61465703 · Mar 23, 2011
Provisional Application 61463212 · Feb 14, 2011
Provisional Application 61462492 · Feb 3, 2011
Related Publication 20170202859A1 · Jul 20, 2017
Cited By (2)
US 12,383,543 US 12,734,180